Jp. Perchellet et al., ANTITUMOR-ACTIVITY OF NOVEL OCTALACTIN A ANALOGS IN MURINE LEUKEMIA-CELLS IN-VITRO, Anticancer research, 18(1A), 1998, pp. 97-106
Octalactin A and B (code names KI and K2) are eight-membered-ring lact
ones from a marine bacterium. KI is reportedly cytotoxic. Since access
to this natural product is severely limited, the entire synthesis of
K1 has been achieved in K. Buszek's laboratory, and several of its str
uctural and stereochemical analogs (code names K3-K9) have been tested
for their ability to prevent murine L1210 leukemic cells from synthes
izing macromolecules and growing in vitro. At 50 mu M, K1 is inactive
and the eight-membered lactone K4, an oxocene, is the only compound fo
und to inhibit tumor cell growth by about 90% in the L1210 system. The
long-term inhibition of L1210 cell growth by K4 is concentration depe
ndent (IC50 around 10 mu M) and not reversible following drug removal.
The delayed and weaker cytotoxic effects of K4 suggest that the inhib
ition of tumor cell proliferation observed 1-4 days after K4 treatment
is not solely caused by drug cytotoxicity. When compared to It spectr
um of representative anticancer drugs, higher concentrations of K4 mus
t be used to maximally inhibit tumor cell growth. In contrast to its a
ntiproliferative activity, 50 mu M K4 fails to alter the rates of DNA,
RNA and protein synthesis in L1210 cells This discrepancy between the
ability of K4 to inhibit macromolecule synthesis and leukemic cell gr
owth suggests that other molecular targets are involved in the antitum
or action of this drug At 50 mu M, K4 inhibits the polymerization of p
urified tubulin by about 45%, and therefore may be a novel microtubule
de-stabilizing drug weaker than vincristine. Even though other mechan
isms may be involved in its antitumor action, the ability of K4 to par
tially disrupt microtubule dynamics indirectly suggests that this synt
hetic oxocene may be a cell cycle-specific anticancer drug that blocks
mammalian cells in M-phase.